Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
If MannKind (NASDAQ:MNKD) could say Afrezza reduces complications such as hypoglycemic events, weight gain, premature organ failure, etc., Afrezza would be one of the most successful product launches in pharmaceutical history. But, here’s the rub. Since they are not going to be able to make such claims at the launch, investors who think otherwise will be disappointed with initial sales results, even though they may be eventually proven right.
This issue arises because Mannkind presented a slide at the FDA Advisory Committee meeting which showed that Afrezza is metabolized over time, much like insulin produced by non-diabetic individuals, which is very different from the way rapid acting analogues are metabolized.
http://www.forbes.com/sites/kenkam/...cceed-but-initial-sales-likely-to-disappoint/
It's a shame so many feel embarrassed about injecting in public
This issue arises because Mannkind presented a slide at the FDA Advisory Committee meeting which showed that Afrezza is metabolized over time, much like insulin produced by non-diabetic individuals, which is very different from the way rapid acting analogues are metabolized.
http://www.forbes.com/sites/kenkam/...cceed-but-initial-sales-likely-to-disappoint/
It's a shame so many feel embarrassed about injecting in public
Last edited: